Literature DB >> 2174825

Depressed lymphokine-activated killer activity and analysis of the precursor cells in peripheral blood of patients with hepatocellular carcinoma.

M Shirai1, S Watanabe, M Nishioka.   

Abstract

The in vitro lymphokine-activated killer activity and natural killer activity of peripheral blood mononuclear cells from 33 patients with hepatocellular carcinoma were investigated. Lymphokine-activated killer and natural killer activities of patients were significantly decreased compared with those of healthy volunteers. Peripheral blood mononuclear cells showed significantly lower lymphokine-activated killer and natural killer activities in patients with larger tumors (greater than or equal to 5 cm in diameter) than in patients with smaller tumors (less than 5 cm in diameter). Of 20 patients with larger tumors, 8 and 6 generated very little or no lymphokine-activated killer and natural killer activities. respectively. Lymphokine-activated killer precursors and natural killer cells were present mainly in the Leu-11+ fraction and partially in the Leu-7+ fraction in patients and normal volunteers. A flow cytometric study showed that the percentage of Leu-7+ 11+ and Leu-7-11+ fractions in peripheral blood mononuclear cells was lower in patients than in normal volunteers. The percentages of Leu-7-11+ and Leu-7+ 11+ fractions were diminished in the peripheral blood mononuclear cells of the patients with little or no lymphokine-activated killer activity. It is suggested that deficient lymphokine-activated killer and natural killer activities partially results from a reduction in the number of their precursor cells in patients with hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174825

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study.

Authors:  Jennifer L Steel; Kevin H Kim; Mary Amanda Dew; Mark L Unruh; Michael H Antoni; Marion C Olek; David A Geller; Brian I Carr; Lisa H Butterfield; T Clark Gamblin
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

2.  Natural killing activities in chronic liver diseases and hepatocellular carcinoma.

Authors:  K Ono; Y Yamanaga; K Yamamoto; S I Koga; J Nishimura; H Nawata
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

3.  Posttraumatic growth, immunity and survival in patients with hepatoma.

Authors:  James T Dunigan; Brian I Carr; Jennifer L Steel
Journal:  Dig Dis Sci       Date:  2007-04-07       Impact factor: 3.199

4.  Opposing behavioural alterations in male and female transgenic TGF alpha mice: association with tumour susceptibility.

Authors:  L A Hilakivi-Clarke; P K Arora; R Clarke; A Wright; M E Lippman; R B Dickson
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.